181 2nd Avenue
3 articles with Dompe U.S.
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
Dompé announces first treatment with Oxervate™ eye drops (cenegermin-bkbj), for neurotrophic keratitis (NK)
Now available through Accredo, Oxervate is the first-in-class recombinant human nerve growth factor (rhNGF) and holds the potential to completely heal NK.
Dompé receives FDA approval of Oxervate™ eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis
Oxervate is the first-ever application of a human nerve growth factor as drug or treatment, and is the first-ever topical biologic medication approved in ophthalmology.